PROKIDNEY CP (PROK)
(Real Time Quote from BATS)
$2.85 USD
-0.33 (-10.38%)
Updated Aug 6, 2025 01:30 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PROK 2.85 -0.33(-10.38%)
Will PROK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PROK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROK
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
Best Momentum Stocks to Buy for July 17th
PROK: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 17th
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Other News for PROK
Largest borrow rate increases among liquid names
BlackRock, Inc. Reduces Stake in ProKidney Corp: A Strategic Portfolio Adjustment
Commit To Purchase ProKidney At $2.50, Earn 64.2% Annualized Using Options
ProKidney (PROK): UBS Raises Price Target to $8.00 | PROK Stock News
ProKidney (PROK) Shares Surge as FDA Approves Accelerated Pathway